British Airways Pensions Investment Management Ltd lessened its stake in Amgen, Inc. (NASDAQ:AMGN) by 58.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,204 shares of the medical research company’s stock after selling 68,174 shares during the period. British Airways Pensions Investment Management Ltd’s holdings in Amgen were worth $8,558,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of AMGN. Schmidt P J Investment Management Inc. grew its holdings in Amgen by 5.0% during the 4th quarter. Schmidt P J Investment Management Inc. now owns 24,772 shares of the medical research company’s stock worth $4,308,000 after acquiring an additional 1,175 shares in the last quarter. Cue Financial Group Inc. grew its holdings in Amgen by 6.5% during the 4th quarter. Cue Financial Group Inc. now owns 6,569 shares of the medical research company’s stock worth $1,142,000 after acquiring an additional 402 shares in the last quarter. WESPAC Advisors LLC bought a new position in Amgen during the 4th quarter worth about $2,053,000. Congress Asset Management Co. MA grew its holdings in Amgen by 3.8% during the 4th quarter. Congress Asset Management Co. MA now owns 37,563 shares of the medical research company’s stock worth $6,532,000 after acquiring an additional 1,389 shares in the last quarter. Finally, Fulcrum Capital LLC bought a new position in Amgen during the 4th quarter worth about $259,000. 78.61% of the stock is currently owned by institutional investors.
Several research analysts have issued reports on AMGN shares. Argus upgraded shares of Amgen from a “hold” rating to a “buy” rating and increased their target price for the stock from $192.33 to $220.00 in a report on Tuesday, January 23rd. Citigroup cut shares of Amgen to a “neutral” rating in a report on Monday, December 18th. JPMorgan Chase & Co. restated a “hold” rating and issued a $191.00 price target on shares of Amgen in a report on Sunday, February 4th. Goldman Sachs Group cut shares of Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Finally, Mizuho set a $192.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $191.72.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the business earned $2.89 earnings per share. analysts anticipate that Amgen, Inc. will post 13.22 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
Amgen announced that its board has approved a share repurchase program on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 4,575 shares of company stock valued at $818,361 over the last quarter. 0.19% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/03/10/amgen-inc-amgn-position-reduced-by-british-airways-pensions-investment-management-ltd.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.